India, March 19 -- Shares of Regenxbio Inc. (RGNX) gained 5% on Wednesday morning after the company reported positive biomarker data from Affinity Duchenne trial of RGX-202 gene therapy.
RGNX is currently trading at $8.21, up $0.41 or 5.26%, on the Nasdaq. The stock opened its trading at $7.90 after closing Tuesday at $7.80. The stock has traded between $5.62 and $23.14 in the past 52-week period.
Regenxbio reported new, positive interim data from two additional patients in the Phase I/II portion of the Affinity Duchenne trial of RGX-202, a differentiated investigational gene therapy for Duchenne muscular dystrophy (Duchenne).
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
"RGX-202 is the only next ...